Phaseline

Targets › NYESO1

NYESO1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on NYESO1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Radboud University Medical CenterPRECIOUS-01
iNKT cell activator (threitolceramide-6/IMM60) and NY-ESO-1 peptide-loaded nanoparticle im
NYESO1Phase 1Advanced Solid TumorDec 2026

Conditions

Advanced Solid Tumor (1)

Modalities

small molecule (1)

Companies

Radboud University Medical Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.